Hong Fang Song - Sep 3, 2025 Form 4 Insider Report for CG Oncology, Inc. (CGON)

Role
Director
Signature
/s/ Joshua F. Patterson, Attorney-in-Fact for Hong Fang Song
Stock symbol
CGON
Transactions as of
Sep 3, 2025
Transactions value $
-$2,779,542
Form type
4
Date filed
9/4/2025, 05:00 PM
Previous filing
Jun 6, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Song Hong Fang Director C/O CG ONCOLOGY, INC., 400 SPECTRUM CENTER DRIVE, SUITE 2040, IRVINE /s/ Joshua F. Patterson, Attorney-in-Fact for Hong Fang Song 2025-09-04 0002008157

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CGON Common Stock Sale -$1.92M -69.7K -2.32% $27.60 2.93M Sep 3, 2025 By Chaming Jade Limited F1, F2, F3
transaction CGON Common Stock Sale -$850K -30.1K -1.03% $28.24 2.9M Sep 3, 2025 By Charming Jade Limited F2, F3, F4
transaction CGON Common Stock Sale -$2.9K -100 0% $28.96 2.9M Sep 3, 2025 By Charming Jade Limited F2, F3
transaction CGON Common Stock Sale -$2.9K -100 0% $28.99 2.9M Sep 3, 2025 By Charming Jade Limited F2, F3
holding CGON Common Stock 587K Sep 3, 2025 By Unique Diamond Investments Limited F3, F5
holding CGON Common Stock 614K Sep 3, 2025 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.94 to $27.93, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F2 Charming Jade Limited is a wholly owned subsidiary of ORI Healthcare Fund II, L.P. ORI Capital II Inc. is the general partner of ORI Healthcare Fund II, L.P. and a wholly owned subsidiary of ORI Holding II Inc.
F3 Each of ORI Holding II Inc. and ORI Capital Holding Inc. is a wholly owned subsidiary of Healthcare Seed Limited. Ms. Song is the sole owner of Healthcare Seed Limited. As a result of these relationships, each of the foregoing entities and Ms. Song may be deemed to share beneficial ownership over the securities held of record by Unique Diamond Investments Limited and Charming Jade Limited, except to the extent of their pecuniary interests therein.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.94 to $28.93, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5 Unique Diamond Investments Limited is a wholly owned subsidiary of ORI Healthcare Fund, L.P. ORI Capital Inc. is the general partner of ORI Healthcare Fund, L.P. and a wholly owned subsidiary of ORI Capital Holding Inc.